Aragen Integrated Drug Discovery (AIDD) offers innovative drug discovery solutions to our partners in their search for new drug candidates. At AIDD, we work in lockstep with our partners to deliver on their drug development strategy
utilizing our specialized, well-trained teams.
With co-located cross functional teams of synthetic chemistry, in-vitro biology, in-vitro & in-vivo pharmacology, ADME, protein production, computational chemistry, process chemistry, formulations and safety assessment studies, we are
best suited to move your candidate towards IND selection.
Our team has a track record of working in a broad range of programs in the small molecule and protein degrader modalities. These programs are aimed at discovering drug candidates that belong to various target classes such as GPCRs, kinases,
transcription factors. They cover multiple therapeutic areas such as Oncology, Neurosciences, Cardiovascular, and are in various stages along the discovery pipeline.
| Therapeutic Area | Target Class | Molecular Class | HIT ID | Lead Opt. | Preclin Cond. | IND Enabling Studies |
|---|---|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | GPCR | @Small Molecule | ||||
| Cardiovascular oncology | Kinase | Protein Degrader | ||||
| oncology | Kinase | Molecular Glue | ||||
| oncology | Tumor Supressor Protein | Small Molecule | ||||
| oncology | Transcription Factor | Small Molecule | ||||
| Neurodegenrative Disease | Hydroxylase | Small Molecule | ||||
| Oncology | mRNA Modulator | Small Molecule | ||||
| Neuroinflemmation | Metabolic Enzymes | Small Molecule |
